Hemogenyx Pharmaceuticals Plc (LON:HEMO – Get Free Report)’s share price reached a new 52-week low on Tuesday . The company traded as low as GBX 175 ($2.28) and last traded at GBX 180.30 ($2.35), with a volume of 39831 shares. The stock had previously closed at GBX 184.75 ($2.40).
Hemogenyx Pharmaceuticals Price Performance
The company has a current ratio of 4.38, a quick ratio of 6.72 and a debt-to-equity ratio of 90.87. The firm’s 50-day moving average price is GBX 325.80 and its 200-day moving average price is GBX 163.74. The stock has a market capitalization of £6.33 million, a PE ratio of -908.65 and a beta of 3.14.
About Hemogenyx Pharmaceuticals
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.
Featured Articles
- Five stocks we like better than Hemogenyx Pharmaceuticals
- How to find penny stocks to invest and trade
- Everything About Amazon Stock Signals a Buy—Time to Load Up?
- Stock Dividend Cuts Happen Are You Ready?
- 5 Reasons Five Below’s Stock Price Is Heading Higher This Year
- Stock Sentiment Analysis: How it Works
- Broadcom: Why the Chip Stock Remains a Top Long-Term AI Play
Receive News & Ratings for Hemogenyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemogenyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
